RZLTRezolute, Inc.

Nasdaq rezolutebio.com


$ 4.70 $ 0.40 (9.3 %)    

Monday, 26-Aug-2024 15:59:37 EDT
QQQ $ 474.46 $ -4.66 (-0.97 %)
DIA $ 412.48 $ 0.89 (0.22 %)
SPY $ 560.78 $ -1.34 (-0.24 %)
TLT $ 98.13 $ -0.25 (-0.25 %)
GLD $ 232.75 $ 0.74 (0.32 %)
$ 4.7
$ 4.67 x 100
-- x --
-- - --
$ 0.72 - $ 6.10
334,249
na
188.64M
$ 31.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 02-13-2024 12-31-2023 10-Q
3 11-13-2023 09-30-2023 10-Q
4 09-14-2023 06-30-2023 10-K
5 05-11-2023 03-31-2023 10-Q
6 02-10-2023 12-31-2022 10-Q
7 11-09-2022 09-30-2022 10-Q
8 09-15-2022 06-30-2022 10-K
9 05-12-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-Q
11 11-12-2021 09-30-2021 10-Q
12 09-15-2021 06-30-2021 10-K
13 05-17-2021 03-31-2021 10-Q
14 02-10-2021 12-31-2020 10-Q
15 11-12-2020 09-30-2020 10-Q
16 10-13-2020 06-30-2020 10-K
17 05-14-2020 03-31-2020 10-Q
18 02-12-2020 12-31-2019 10-Q
19 11-14-2019 09-30-2019 10-Q
20 09-10-2019 06-30-2019 10-K
21 05-10-2019 03-31-2019 10-Q
22 02-14-2019 12-31-2018 10-Q
23 12-14-2018 09-30-2018 10-Q
24 10-15-2018 06-30-2018 10-K
25 05-15-2018 03-31-2018 10-Q
26 02-14-2018 12-31-2017 10-Q
27 11-14-2017 09-30-2017 10-Q
28 09-22-2017 06-30-2017 10-K
29 05-15-2017 03-31-2017 10-Q
30 02-02-2017 12-31-2016 10-Q
31 11-14-2016 09-30-2016 10-Q
32 09-28-2016 06-30-2016 10-K
33 05-16-2016 03-31-2016 10-Q
34 02-16-2016 12-31-2015 10-Q
35 11-16-2015 09-30-2015 10-Q
36 09-28-2015 06-30-2015 10-K
37 05-15-2015 03-31-2015 10-Q
38 02-17-2015 12-31-2014 10-Q
39 11-12-2014 09-30-2014 10-Q
40 09-30-2014 06-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 maxim-group-maintains-buy-on-rezolute-raises-price-target-to-10

Maxim Group analyst Jason McCarthy maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $8 to $10.

 hc-wainwright--co-reiterates-buy-on-rezolute-maintains-14-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.

 rezolute-gets-fda-clearance-for-rz358-to-treat-hypoglycemia-in-tumor-hyperinsulinism

Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company committed to...

 btig-initiates-coverage-on-rezolute-with-buy-rating-announces-price-target-of-13

BTIG analyst Julian Harrison initiates coverage on Rezolute (NASDAQ:RZLT) with a Buy rating and announces Price Target of $13.

 rezolute-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-no-size-or-amount-disclosed

Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company committed to...

 craig-hallum-initiates-coverage-on-rezolute-with-buy-rating-announces-price-target-of-14

Craig-Hallum analyst Christian Schwab initiates coverage on Rezolute (NASDAQ:RZLT) with a Buy rating and announces Price Tar...

Core News & Articles
Market-Moving News for May 22nd
05/22/2024 12:34:04

CRNX: 11% | Crinetics Pharmaceuticals shares are trading higher after the company announced the early release of ENDO 2024 late...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION